Cargando…

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain

BACKGROUND: The current economic recession in European countries has forced governments to design emergency measures to reduce spending on drugs, including antiretroviral therapy (ART). Switching antiretroviral drugs for others that have the same efficacy and safety profile at a lower cost (cost-red...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llibre, Josep M, Cardona, Gloria, Santos, José R, Andreu, Angels, Estrada, Josep O, Ara, Jordi, Bonafont, Xavier, Clotet, Bonaventura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666549/ https://www.ncbi.nlm.nih.gov/pubmed/23723714 http://dx.doi.org/10.2147/CEOR.S43662

Ejemplares similares

Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging
por: Llibre-Codina, Josep M, et al.
Publicado: (2014)

Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging
por: Andreu-Crespo, Àngels, et al.
Publicado: (2015)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Predictors of Viremia in Postpartum Women on Antiretroviral Therapy
por: Hoffman, Risa M., et al.
Publicado: (2020)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
por: Jacobs, Jana L., et al.
Publicado: (2019)

Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE)
por: Cheng, Chien-Yu, et al.
Publicado: (2014)

Reduced adherence to antiretroviral therapy is associated with residual low-level viremia
por: Maggiolo, Franco, et al.
Publicado: (2017)

Factors associated with viremia in people living with HIV on antiretroviral therapy in Guatemala
por: Ortíz, Dean W., et al.
Publicado: (2021)

Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy
por: Weissmann, Leonardo, et al.
Publicado: (2019)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens
por: Llibre, Josep M., et al.
Publicado: (2022)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
por: Lukhwareni, Azwidowi, et al.
Publicado: (2020)

Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy
por: Bakkour, Sonia, et al.
Publicado: (2020)

Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy
por: Jacobs, Jana L., et al.
Publicado: (2020)

Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2021)

Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia
por: Sokpa, Darryl, et al.
Publicado: (2022)

Cardiovascular Profile of South African Adults with Low-Level Viremia during Antiretroviral Therapy
por: Botha-Le Roux, Shani, et al.
Publicado: (2022)

Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia
por: Konstantopoulos, Christina, et al.
Publicado: (2015)

Antiretroviral Treatment-Induced Galectin-9 Might Impact HIV Viremia in Addition to Contributing to Inflammaging
por: Shete, Ashwini, et al.
Publicado: (2023)

Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients
por: Delaugerre, Constance, et al.
Publicado: (2012)

Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy
por: Gaifer, Zied, et al.
Publicado: (2020)

Antiretroviral therapy suppressed participants with low CD4(+) T-cell counts segregate according to opposite immunological phenotypes
por: Pérez-Santiago, Josué, et al.
Publicado: (2016)

Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings
por: López Seguí, Francesc, et al.
Publicado: (2021)

Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy
por: Gálvez, Cristina, et al.
Publicado: (2021)

HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy
por: Mavigner, Maud, et al.
Publicado: (2009)

1564 Duration of Viral Suppression and objectively measured Antiretroviral Adherence as predictors of rebound Viremia in South Western Uganda
por: Musinguzi, Nicholas
Publicado: (2014)

Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
por: Elvstam, Olof, et al.
Publicado: (2017)

Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya
por: Aoko, Appolonia, et al.
Publicado: (2023)

Benefits and limitations of different study designs for long‐acting antiretroviral therapy among people living with HIV with viremia
por: Gandhi, Monica, et al.
Publicado: (2023)

Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho
por: Amstutz, Alain, et al.
Publicado: (2020)

Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
por: Estrada, Vicente, et al.
Publicado: (2022)

Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?
por: Horne, Robert, et al.
Publicado: (2009)

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
por: Mellberg, Tomas, et al.
Publicado: (2011)

A Tonsillar PolyICLC/AT-2 SIV Therapeutic Vaccine Maintains Low Viremia Following Antiretroviral Therapy Cessation
por: Vagenas, Panagiotis, et al.
Publicado: (2010)

HIV low-level persistent viremia under new antiretroviral regimens: what we have learned up to this point?
por: Gheorghiță, Valeriu, et al.
Publicado: (2014)

Association of Residual Plasma Viremia and Intima-Media Thickness in Antiretroviral-Treated Patients with Controlled Human Immunodeficiency Virus Infection
por: Boyd, Anders, et al.
Publicado: (2014)

Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients
por: Archampong, Timothy N. A., et al.
Publicado: (2016)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy
por: Behrens, Nicole E., et al.
Publicado: (2020)

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
por: Santos, José R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_arao747e2nm39hc0igbr2hi86s